Incyte (NASDAQ:INCY) delivered a robust finish to 2025 on Tuesday, February 10, 2026, marking its first year crossing the $5 billion revenue threshold.
The Wilmington-based biopharmaceutical company reported total fourth-quarter revenue of $1.51 billion, a 28% jump year-over-year, while full-year revenue climbed 21% to $5.14 billion.
The performance was anchored by the company’s "Big Two"—Jakafi and Opzelura—which continue to dominate the myelofibrosis and dermatology markets, respectively.
Total net product revenue for the fourth quarter hit $1.22 billion, a 20% increase that reflected resilient demand for Jakafi, which remains the standard of care in myelofibrosis.
Opzelura, the company's ruxolitinib cream, continued its rapid ascent in the vitiligo and atopic dermatitis spaces, contributing to a full-year product revenue of $4.35 billion—exceeding the company’s own upper-bound guidance.
Additionally, the quarter was bolstered by $100 million in milestone and contract revenue, highlighting the maturation of Incyte’s global partnership network.
CEO Bill Meury, who joined the company in mid-2025, described the results as "exceptional core business growth."
Beyond the commercial success, Incyte is aggressively pivoting toward its next generation of growth drivers.
The company enters 2026 with 14 pivotal clinical trials underway and recently saw strong early uptake for Niktimvo™ in chronic GVHD.
Looking ahead, Incyte provided a confident 2026 roadmap, targeting total net product revenue between $4.77 billion and $4.94 billion.